Proteomics International Laboratories Limited
ASX: PIQ
PromarkerD launches in AU/US with CLIA lab and CPT/PLA code, oversold RSI hints at rebound potential.
(Source: TradingView) 3-Month Performance Profile of PIQ on a DTF compared to S&P/ASX 200 (XJO).
Proteomics International advanced its commercialization strategy in FY25 with the launch of its next-gen PromarkerD test in Australia and
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
